Search for: "Sanofi-Aventis US LLC"
Results 1 - 20
of 83
Sort by Relevance
|
Sort by Date
24 Nov 2023, 6:08 pm
Greene’s Energy Group, LLC, 138 S. [read post]
11 May 2023, 10:12 am
By Chris Holman Sanofi-Aventis Deutschland GMBH v. [read post]
9 Aug 2021, 2:22 pm
Sanofi-Aventis U.S. [read post]
2 May 2021, 1:41 pm
Sanofi-Aventis. [read post]
15 Apr 2021, 10:51 am
Sanofi-Aventis U.S. [read post]
28 Dec 2020, 7:04 am
A federal judge refused to narrow a class action lawsuit accusing Sanofi-Aventis US LLC of suppressing competing versions of its diabetes drug Lantus, rejecting the company’s claim that the named plaintiff, FWK Holdings LLC, lacked standing to challenge actions Sanofi took after FWK stopped buying the drug. [read post]
16 Dec 2020, 9:10 am
Sanofi-Aventis U.S. [read post]
9 Nov 2020, 3:00 am
LLC Sanofi US Services Inc. [read post]
9 Nov 2020, 3:00 am
LLC Sanofi US Services Inc. [read post]
9 Nov 2020, 3:00 am
LLC Sanofi US Services Inc. [read post]
15 Oct 2020, 9:40 pm
Sanofi-Aventis U.S. [read post]
5 Oct 2020, 10:25 am
Arthrex, Inc., No. 19-1452; Sanofi-Aventis Deutschland GmbH v. [read post]
27 Sep 2020, 6:36 pm
., No. 19-1452; Sanofi-Aventis Deutschland GmbH v. [read post]
11 Dec 2019, 8:40 am
Zantac Class Action Lawsuits Recently, two class-action lawsuits were filed against Zantac manufacturer Sanofi-Aventis LLC and Boehringer Ingelheim Pharmaceuticals, who previously held rights to Zantac, with plaintiffs claiming that the companies knowingly put patient health at risk. [read post]
24 Oct 2019, 9:24 am
A generic company recently invalidated a number of patents covering Lantus®—an insulin product that nets Sanofi-Aventis $15 million per day and has been the subject of numerous price hikes that far exceed inflation. [read post]
27 Aug 2019, 9:59 pm
The case arose in ANDA litigation involving Sanofi's Jevtana® (cabazitaxel), having the structure: where the methoxy... [read post]
14 Jan 2018, 8:47 am
Andrews in Sanofi-Aventis U.S. [read post]
5 Sep 2017, 7:45 am
On August 17, the Department of Justice announced that the pharmaceutical company Mylan and its subsidiary had agreed to pay $465 million to the federal and state governments to settle allegations, originally brought by the company’s competitor, Sanofi-Aventis US LLC, that it had defrauded the Medicaid program by falsely declaring its epinephrine syringe, the Epi-Pen, to be a generic device. [read post]
25 Aug 2017, 7:02 am
” The allegations against Mylan were brought to court by pharmaceutical manufacturer Sanofi-Aventis US LLC under a provision of the False Claims Act that permits private qui tam whistleblowers to sue alleged wrongdoers on behalf of the federal government. [read post]
25 Aug 2017, 7:02 am
” The allegations against Mylan were brought to court by pharmaceutical manufacturer Sanofi-Aventis US LLC under a provision of the False Claims Act that permits private qui tam whistleblowers to sue alleged wrongdoers on behalf of the federal government. [read post]
